NASDAQ:BLRX

BioLineRx (BLRX) Stock Price, News & Analysis

BioLineRx logo
$1.16 +0.01 (+0.43%)
Closing price 03:59 PM Eastern
Extended Trading
$1.15 -0.01 (-0.61%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About BioLineRx Stock (NASDAQ:BLRX)

Advanced

Key Stats

Today's Range
$1.11
▼
$1.29
50-Day Range
$1.15
▼
$2.60
52-Week Range
$1.11
▼
$3.95
Volume
32,425 shs
Average Volume
25,888 shs
Market Capitalization
$5.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

BioLineRx Ltd. is an Israel-based biopharmaceutical company that develops therapies for cancer and other serious diseases. Founded in 2003, the company advances drug candidates through clinical development and works with commercial and development partners.

Its lead product, motixafortide, is marketed in the United States as Aphexda. The FDA approved Aphexda, in combination with filgrastim, to mobilize hematopoietic stem cells for collection in adults with multiple myeloma who are preparing for autologous transplantation. BioLineRx has also studied motixafortide in clinical trials for conditions including pancreatic cancer.

BioLineRx’s activities span Israel and international markets, with its research and clinical programs involving partners and trial sites in multiple countries. The company continues to develop additional drug candidates and investigate potential uses for motixafortide.

AI Generated. May Contain Errors.

BioLineRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

BLRX MarketRank™: 
0.579931071045 of 5 stars

BioLineRx scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioLineRx has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    BioLineRx has only been the subject of 1 research reports in the past 90 days.

  • Read more about BioLineRx's stock forecast and price target.
  • Earnings Growth

    Earnings for BioLineRx are expected to grow in the coming year, from ($1.57) to ($1.26) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioLineRx is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioLineRx is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioLineRx has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about BioLineRx's valuation and earnings.
  • Percentage of Shares Shorted

    2.77% of the float of BioLineRx has been sold short.
  • Short Interest Ratio / Days to Cover

    BioLineRx has a short interest ratio ("days to cover") of 17.18, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in BioLineRx has recently decreased by 0.28%, indicating that investor sentiment is improving.
  • Dividend Yield

    BioLineRx does not currently pay a dividend.

  • Dividend Growth

    BioLineRx does not have a long track record of dividend growth.

  • News Sentiment

    BioLineRx has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for BioLineRx this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added BioLineRx to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioLineRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.10% of the stock of BioLineRx is held by insiders.

  • Percentage Held by Institutions

    1.56% of the stock of BioLineRx is held by institutions.

  • Read more about BioLineRx's insider trading history.
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BLRX Stock News Headlines

BioLineRx (BLRX) Set to Release Quarterly Earnings on Monday
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
See More Headlines

BLRX Stock Analysis - Frequently Asked Questions

BioLineRx's stock was trading at $2.77 on January 1st, 2026. Since then, BLRX shares have decreased by 56.7% and is now trading at $1.20.

BioLineRx Ltd. (NASDAQ:BLRX) announced its quarterly earnings results on Friday, August, 28th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.62. The biotechnology company earned $294 thousand during the quarter, compared to analyst estimates of $500 thousand. BioLineRx had a negative net margin of 502.08% and a negative trailing twelve-month return on equity of 34.80%.
Read the conference call transcript
.

BioLineRx's stock reverse split before market open on Thursday, January 30th 2025.The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include NVIDIA (NVDA), Tesla (TSLA), Viking Therapeutics (VKTX), Tonix Pharmaceuticals (TNXP), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and SCYNEXIS (SCYX).

Company Calendar

Last Earnings
8/28/2026
Today
11/17/2026
Next Earnings (Estimated)
11/23/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BLRX
CIK
1498403
Employees
22
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$1.17 million
Net Margins
-502.08%
Pretax Margin
-728.45%
Return on Equity
-34.80%
Return on Assets
-18.27%

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
1.20
Quick Ratio
1.04

Sales & Book Value

Annual Sales
$1.18 million
Price / Sales
4.87
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.36 per share
Price / Book
0.22

Miscellaneous

Outstanding Shares
4,980,000
Free Float
4,923,000
Market Cap
$5.75 million
Optionable
Optionable
Beta
1.64
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:BLRX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners